New Trial for Patients with Ovarian Cancer: AGO-OVAR

The trial will investigate whether the addition of the active substance atezolizumab to standard treatment with chemotherapy and bevacizumab prolongs patient survival.
Various studies indicate that the combination of an angiogenesis inhibitor (bevacizumab) and an immunotherapeutic (atezolizumab) in tumor therapy could have a clinical benefit with acceptable tolerability. This combination will therefore now be investigated in AGO-OVAR. Around 200 centers worldwide, including 13 centers in Switzerland, will participate in the trial, with the aim of enrolling 664 patients.

Further information on the AGO-OVAR trial can be found here.